The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: A cost-utility analysis

Journal of Viral Hepatitis

Volumn 15, Issue 11, 2008, Pages 797-808

  Sutton, A J ^a,b   Edmunds, W J ^a   Sweeting, M J ^c   Gill, O N ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cost effectiveness; Hepatitis C; Injecting drug users; Prisons; Treatment

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE COST; HEPATITIS C; HUMAN; INFECTION CONTROL; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MASS SCREENING; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRISON; QUALITY OF LIFE; SENSITIVITY ANALYSIS; TREATMENT PLANNING; UNITED KINGDOM;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; ENGLAND; HEPATITIS C; HUMANS; MIDDLE AGED; PRISONS; WALES;

EID: 54849439744     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01008.x     Document Type: Article

References (29)

1. Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Commun Dis Public Health 2000 3 (2 121 126.
2. Sutton AJ, Gay NJ, Edmunds WJ et al. Modelling the hepatitis B vaccination programme in prisons. Epidemiol Infect 2006 134 (2 231 242.
3. Castelnuovo E, Thompson-Coon J, Pitt M et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006 10 (32 1 112.
4. Sweeting MJ, de Angelis D, Neal KR et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol 2006 59 (2 144 152.
5. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London : National Institute for Health and Clinical Excellence, 2004.
6. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis 2006 6 (1 93.
7. Stein K, Dalziel K, Walker A et al. Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess 2002 6 (31 1 122.
8. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. Hepatology 2006 44 (5 1139 1145.
9. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003 52 (10 1500 1504.
10. Sutton AJ, Edmunds WJ, Gill ON. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health 2006 6 (1 170.
11. Horne JA, Clements AJ, Drennan P, Stein K, Cramp ME. Screening for hepatitis C virus in the Dartmoor prison population: an observational study. J Public Health (Oxf) 2004 26 (4 372 375.
12. Serfaty MA, Lawrie A, Smith B et al. Risk factors and medical follow-up of drug users tested for hepatitis C - can the risk of transmission be reduced? Drug Alcohol Rev 1997 16 (4 339 347.
13. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001 8 (2 87 95.
14. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997 112 (2 463 472.
15. Siebert U, Sroczynski G, Rossol S et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003 52 (3 425 432.
16. Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006 10 (21 1 130.
17. Office for National Statistics. Deaths: Age and Sex, Numbers and Rates, 1976 onwards. London : Office for National Statistics, 2005.
18. de Angelis D, Hickman M, Yang S. Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol 2004 160 (10 994 1004.
19. National Institute for Health and Clinical Excellence G. Peginterferon Alfa and Ribavirin for the Treatment of Mild Chronic Hepatitis C. London : National Institute for Health and Clinical Excellence, 2006.
20. British National Formulary. London : British Medical Association and Royal Pharmaceutical Society of Great Britain, 2005.
21. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004 8 (39 iii 125.
22. Coon JT, Castelnuovo E, Pitt M, Cramp M, Siebert U, Stein K. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract 2006 23 (4 393 406.
23. National Institute for Health and Clinical Excellence. Interferon Alfa (pegylated and non-pegylated) and Ribavirin for the Treatment of Chronic Hepatitis C. London : National Institute for Health and Clinical Excellence, 2004.
24. Hadziyannis SJ, Sette Jr H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 (5 346 355.
25. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 (6 696 699.
26. Lim JK. Natural history of hepatitis C infection: a concise review. Yale J Biol Med 2001 74 (4 229 237.
27. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005 3 (11 1150 1159.
28. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999 30 (5 1299 1301.
29. Spaulding AC, Weinbaum CM, Lau DT et al. A framework for management of hepatitis C in prisons. Ann Intern Med 2006 144 (10 762 769.